Amit Bar-Or, MD, FRCP, FAAN, FANA

Medical School

MD - McGill University, Montreal, Québec

Internship

Medicine - Massachusetts General Hospital (MGH), Harvard Medical School (HMS), Boston, MA

Fellowship

Neurology - Massachusetts General Hospital (MGH), Harvard Medical School (HMS), Boston, MA

Postdoctoral Research Fellow, Clinical Investigator Training Program - Harvard Medical School (HMS), Massachusetts Institute of Technology, Boston, MA

Neurology - Brigham and Women's Hospital, Boston, MA

Postdoctoral Research Fellow, Cellular and Molecular Immunology, Center for Neurologic Disease, Harvard Medical School, Boston, MA

Papers

2017

Ghadiri M, Rezk A, Li R, Evans A, Luessi F, Zipp F, Giacomini PS, Antel J: Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurol Neuroimmunol Neuroinflamm 4(3), Mar 2017.

Aubert-Broche B, Weier K, Longoni G, Fonov VS, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Verhey LH, Banwell B, Collins DL; : Monophasic demyelination reduces brain growth in children  Neurology April 2017.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L: OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 376(3): 221-234, Jan 2017.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky J: ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J. 376(3): 221-234, Jan 2017.

Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A*: Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis. J Immunol. 198(2): 691--698, Jan 2017.

2016

Rozenberg A, Rezk A, Boivin MN, Darlington PJ, Nyirenda M, Li R, Jalili F, Winer R, Artsy EA, Uccelli A, Reese JS, Planchon SM, Cohen JA, Bar-Or A: Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. Stem Cells Transl Med. pii: sctm.2015-0243(11), Jul 2016.

Makhani N, Banwell B, Tellier R, Yea C, McGovern S, O'Mahony J, Ahorro JM, Arnold D, Sadovnick AD, Marrie RA, Bar-Or A; Canadian Pediatric Demyelinating Disease Network: Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination. Mult Scler 22(3): 385-8, Mar 2016.

2015

Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, Moore C, Michel L, Althekair F, Rajasekharan S, Gommerman J, Prat A, Fillatreau S and Bar-Or A on behalf of the 'Canadian B cells in MS Team': Proinflammatory GM-CSF producing B cells: implication in multiple sclerosis and B cell depletion therapy. Sci Transl Med 7(310): 166, Oct 2015.

Bar-Or A, Wiendl H, Miller B, Benamor M, Truffinet P, Church M, Menguy-Vacheron F: Randomized study of teriflunomide effects on immune responses to neo-antigen and recall antigens. Neurol Neuroimmunol Neuroinflamm. 2(2): e70, Feb 2015.

Moore CS, Cui QL, Warsi NM, Durafourt BA, Zorko N, Owen DR, Antel JP, and Bar-Or A: Direct and Indirect Effects of Immune and Central Nervous System–Resident Cells on Human Oligodendrocyte Progenitor Cell Differentiation. J Immunol 194(2): 761-72, Jan 2015.